Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial

• Published in: Multiple sclerosis 2024-05, Vol.30 (6), p.687-695
• Main Authors: Nakamura, Kunio, Sun, Zhaonan, Hara-Cleaver, Claire, Bodhinathan, Karthik, Avila, Robin L
• Format: Article
• Language: English
• Subjects: Adult; Atrophy; Atrophy - pathology; Cognitive ability; Deep Learning; Female; Gray Matter - diagnostic imaging; Gray Matter - drug effects; Gray Matter - pathology; Humans; Image processing; Immunologic Factors - pharmacology; Inflammation; Magnetic Resonance Imaging; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - pathology; Natalizumab - pharmacology; Natalizumab - therapeutic use; Placebos; Substantia grisea; Thalamus; Thalamus - diagnostic imaging; Thalamus - drug effects; Thalamus - pathology
• ISSN: 1352-4585; 1477-0970
• DOI: 10.1177/13524585241235055

Background: Loss of brain gray matter fractional volume predicts multiple sclerosis (MS) progression and is associated with worsening physical and cognitive symptoms. Within deep gray matter, thalamic damage is evident in early stages of MS and correlates with physical and cognitive impairment. Natalizumab is a highly effective treatment that reduces disease progression and the number of inflammatory lesions in patients with relapsing-remitting MS (RRMS). Objective: To evaluate the effect of natalizumab on gray matter and thalamic atrophy. Methods: A combination of deep learning–based image segmentation and data augmentation was applied to MRI data from the AFFIRM trial. Results: This post hoc analysis identified a reduction of 64.3% (p = 0.0044) and 64.3% (p = 0.0030) in mean percentage gray matter volume loss from baseline at treatment years 1 and 2, respectively, in patients treated with natalizumab versus placebo. The reduction in thalamic fraction volume loss from baseline with natalizumab versus placebo was 57.0% at year 2 (p < 0.0001) and 41.2% at year 1 (p = 0.0147). Similar findings resulted from analyses of absolute gray matter and thalamic fraction volume loss. Conclusion: These analyses represent the first placebo-controlled evidence supporting a role for natalizumab treatment in mitigating gray matter and thalamic fraction atrophy among patients with RRMS. ClinicalTrials.gov identifier: NCT00027300 URL: https://clinicaltrials.gov/ct2/show/NCT00027300